Vikas V Dukhande

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 8

Top Venues

Cancers

Nanomedicine (London, England)

Pharmaceutics

Pharmaceutical research

St. John's University

This page only lists publications with an associated author ORCID identifier.

Affiliation History

St. John's University

United States

Assistant Professor :: Pharmaceutical Sciences

Publications

Shraddha Bhutkar, Anjali Yadav, Himaxi Patel, Shrikant Barot, Ketankumar Patel, Vikas V Dukhande
Synergistic Efficacy of CDK4/6 Inhibitor Abemaciclib and HDAC Inhibitor Panobinostat in Pancreatic Cancer Cells. Cancers 16 (15) (2024)
Shraddha Bhutkar, Anjali Yadav, Himaxi Patel, Shrikant Barot, Ketankumar Patel, Vikas V Dukhande
Synergistic Efficacy of CDK4/6 Inhibitor Abemaciclib and HDAC Inhibitor Panobinostat in Pancreatic Cancer Cells. Cancers 16 (15) (2024)
Shraddha Bhutkar, Anjali Yadav, Himaxi Patel, Shrikant Barot, Ketankumar Patel, Vikas V Dukhande
Synergistic Efficacy of CDK4/6 Inhibitor Abemaciclib and HDAC Inhibitor Panobinostat in Pancreatic Cancer Cells. Cancers 16 (15) (2024)
Anjali Yadav, Ali Alnakhli, Hari Priya Vemana, Shraddha Bhutkar, Aaron Muth, Vikas V Dukhande
Repurposing an Antiepileptic Drug for the Treatment of Glioblastoma. Pharmaceutical research 39 (11) (2022)
Hari Priya Vemana, Vikas V Dukhande
Recent advances in the application of nanomedicine for the treatment of diabetes. Nanomedicine (London, England) 17 (2) (2022)
Yige Fu, Aishwarya Saraswat, Zenghui Wei, Manas Yogendra Agrawal, Vikas V Dukhande, Sandra E Reznik, Ketankumar Patel
Development of Dual ARV-825 and Nintedanib-Loaded PEGylated Nano-Liposomes for Synergistic Efficacy in Vemurafnib-Resistant Melanoma. Pharmaceutics 13 (7) (2021)
Hari Priya Vemana, Aishwarya Saraswat, Shraddha Bhutkar, Ketan Patel, Vikas V Dukhande
A novel gene therapy for neurodegenerative Lafora disease via EPM2A-loaded DLinDMA lipoplexes. Nanomedicine (London, England) 16 (13) (2021)
Yige Fu, Drishti Rathod, Ehab M Abo-Ali, Vikas V Dukhande, Ketankumar Patel
EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAFV600E Mutated Parent- and Vemurafenib-Resistant Melanoma. Pharmaceutics 11 (10) (2019)

Vikas V Dukhande.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Vikas V Dukhande